RHBC
ADPT icon

R.H. Bluestein & Co’s Adaptive Biotechnologies ADPT Stock Holding History

R.H. Bluestein & Co’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,500
Closed -$207K – 407
2020
Q4 		$207K Buy
+3,500
New +$180K 0.01% 366

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

R.H. Bluestein & Co's ADPT Position: Q1 2021 in Review

R.H. Bluestein & Co sold out of Adaptive Biotechnologies (ADPT) in Q1 2021, closing a stake of 3,500 shares — an estimated $207K sold.

R.H. Bluestein & Co first reported a position in ADPT in Q4 2020 and held it in 1 quarter. The position peaked at $207K in Q4 2020. 248 funds tracked by Wall St. Rank hold ADPT as of Q1 2021.

  • R.H. Bluestein & Co reported no remaining Adaptive Biotechnologies position as of Q1 2021 after selling out during the quarter.
  • R.H. Bluestein & Co sold 3,500 Adaptive Biotechnologies shares in Q1 2021, an estimated $207K.
  • R.H. Bluestein & Co first reported a position in Adaptive Biotechnologies in Q4 2020 and held it in 1 quarter.
  • R.H. Bluestein & Co's Adaptive Biotechnologies position peaked at $207K in Q4 2020.
  • 248 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2021.

Based on R.H. Bluestein & Co's 13F filing for Q1 2021, filed 12 May 2021.